MARKET

CRVO

CRVO

CervoMed
NASDAQ
3.240
+0.350
+12.11%
Closed 16:10 05/20 EDT
OPEN
2.960
PREV CLOSE
2.890
HIGH
3.270
LOW
2.870
VOLUME
97.24K
TURNOVER
0
52 WEEK HIGH
13.13
52 WEEK LOW
2.815
MARKET CAP
30.00M
P/E (TTM)
-0.9913
1D
5D
1M
3M
1Y
5Y
1D
Boris Peaker Reiterates Buy on Neflamapimod Developer, Backs $20 Price Target on Pivotal DLB Phase III and Broad 2026 Clinical Catalysts
TipRanks · 1d ago
CervoMed Highlights Q1 Results and Neflamapimod Progress
TipRanks · 2d ago
CervoMed price target lowered to $9 from $11 at Roth Capital
TipRanks · 2d ago
CervoMed reports Q1 results
Seeking Alpha · 2d ago
CervoMed posts smaller-than-expected Q1 net loss 
Reuters · 2d ago
*CervoMed Expects EXPERTS-ALS to Dose First Patient With ALS With Neflamapimod by End of 2026 >CRVO
Dow Jones · 2d ago
*CervoMed Continued Progress Towards Initiating Planned Phase 3 Trial Evaluating Neflamapimod in Patients With Dementia With Lewy Bodies in 2H >CRVO
Dow Jones · 2d ago
*CervoMed 1Q Loss $8M >CRVO
Dow Jones · 2d ago
More
About CRVO
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.

Webull offers CervoMed Inc stock information, including NASDAQ: CRVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRVO stock methods without spending real money on the virtual paper trading platform.